COPI Notices extended for a further three months until 30 June 2022

Simon Madden, Director of Data Policy at NHSX ,on behalf of the Secretary of State for Health and Social Care, notified GP practices on 10 February 2022 that the COPI notice which was set to expire on 31 March 2022 has been extended for a further three months until 30 June 2022.

Under the COPI notice organisations are only required to process confidential patient information (CPI):

  • where the CPI to be processed is required for a COVID-19 purpose and will processed solely for that COVID-19 purpose in accordance with Regulation 7 of COPI
  • from the date of this notice (10 February 2022) until 30 June 2022 (this also includes a case where the dissemination of the CPI in question was authorised under a previous COPI notice which began before the 10 February 2022 and where the processing is set to continue after this date).

The NHS Transformation Directorate have advised organisations to use the short extension of the COPI notice to prepare and ensure that all processing which relies on the COPI notices is ready to cease or move to an alternative sustainable legal basis by 30 June 2022.

In addition, the COPI notice to GP Practices in England whose IT systems are supplied by TPP or EMIS requiring them to release primary care patient data, in respect of UK Biobank’s consented participants only, to UK Biobank, for the purposes set out in Regulation 3(1) of COPI has also been extended until 30 June 2022.

For background information: Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002  (COPI Regulations) enables those working for the purposes of the health service, and other organisations employed by a public authority in communicable disease surveillance, to share confidential patient information (CPI) to respond to communicable diseases and other threats to public health. It also allows the Secretary of State to issue notices requiring that CPI be shared for such purposes.

Last updated : 22 Feb 2022


Islington LMC Newsletter - January 2022 (31 Jan 2022)

Please click here to read the latest Islington LMC news update.
Read more »

Tips of the month January 2022 (19 Jan 2022)

We provide weekly tips based on common queries which come through to us from London GPs and practice teams. These are shared via social media and collated for...
Read more »

Fuller report response (19 Jan 2022)

Professor Claire Fuller is leading a wide-ranging national stocktake of how best primary care can be supported within the emergent Integrated Care Systems (ICS). The focus of the work will be on...
Read more »

Online and video consultation data collection (19 Jan 2022)

A data provision notice (DPN) for a data collection on Online and Video Consultation in General Practices  was issued to general practices in England on 10 January 2022. NHS...
Read more »

PANORAMIC study (19 Jan 2022)

Dr David Mummery is a member of Hammersmith and Fulham LMC and Clinical Speciality Lead for Primary Care, North West London Clinical Research Network. He writes here about why practice participation...
Read more »

General practice issues in Parliament (19 Jan 2022)

In December, the House of Commons’ Health and Social Care Committee published their report on clearing the backlog caused by the pandemic. Research by the Institute for Fiscal...
Read more »

Managing a remote team module - applications now open (19 Jan 2022)

Runs: online, with a taught day on 4 February 2022 Costs: £325 + VAT This module is suitable for anyone working in a position of management or leadership where members...
Read more »

December 2021 workforce survey results (19 Jan 2022)

Thank you for taking the time to complete our December 2021 workforce survey at time when practice teams were so overstretched. We had 327 responses from 277 individual member practices, of...
Read more »

Covid-19 antiviral pilots (16 Dec 2021)

The government announced this month that thousands of the UK’s most vulnerable people will be among the first in the world to access a new antiviral treatment for Covid-19, Molnupiravir....
Read more »
Next Page »
« Previous Page